Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options

References

• Kebebew E, Reiff E, Duh QY, et al. Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress? World J Surg. 2006;30:872–878.
   PubMed Web of Science ®Google Scholar
• Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical carcinoma: a population-based study on incidence and survival in the Netherlands since 1993. Eur J Cancer. 2013;49:2579–2586.
   PubMed Web of Science ®Google Scholar
• Stigliano A, Chiodini I, Giordano R, et al. Management of adrenocortical carcinoma: a consensus statement of the Italian society of endocrinology (SIE). J Endocrinol Invest. 2016;39(1):103–121.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic value of the 2004 international union against cancer staging classification for adrenocortical carcinoma. Cancer. 2009;115(2):243–250.
   PubMed Web of Science ®Google Scholar
• Petr EJ, Else T. Genetic predisposition to endocrine tumors: diagnosis, surveillance and challenges in care. Semin Oncol. 2016;43:582–590.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Libé R, Kroiss M, et al. Adrenocortical carcinoma: a clinician’s update. Nat Rev Endocrinol. 2011;7(6):323–335.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Arlt W, Bancos I, et al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol. 2016;175:G1–G34.
   PubMed Web of Science ®Google Scholar
• Else T, Kim AC, Sabolch A, et al. Adrenocortical carcinoma. Endocr Rev. 2014;35:282–326.
   PubMed Web of Science ®Google Scholar
• Dinnes J, Bancos I, Ferrante di Ruffiano L, et al. MANAGEMENT OF ENDOCRINE DISEASE: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol. 2016;175:R51–64.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Bovio S, Pia A, et al. Management of adrenal incidentaloma. Best Pract Res. 2009;23(2):233–243.
   Web of Science ®Google Scholar
• Eller-Vainicher C, Morelli V, Salcuni AS, et al. Accuracy of several parameters of hypothalamic-pituitary-adrenal axis activity in predicting before surgery the metabolic effects of the removal of an adrenal incidentaloma. Eur J Endocrinol. 2010;163:925–935.
   PubMed Web of Science ®Google Scholar
• Seccia TM, Fassina A, Nussdorfer GG, et al. Aldosterone-producing adrenocortical carcinoma: an unusual cause of Conn’s syndrome with an ominous clinical course. Endocr Relat Cancer. 2005;12:149–159.
   PubMed Web of Science ®Google Scholar
• Funder JW, Carey RM, Mantero F, et al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2016;101:1889–1916.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Alì A, Osella G, et al. The value of dehydroepiandrosterone sulfate measurement in the differentiation between benign and malignant adrenal masses. Eur J Endocrinol. 2000;142:611–617.
   PubMed Web of Science ®Google Scholar
• Taylor DR, Ghataore L, Couchman L, et al. A 13-steroid serum panel based on LC-MS/MS: use in detection of adrenocortical carcinoma. Clin Chem. 2017;63:1836–1846.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Stigliano A, Chiodini I, et al. AME position statement on adrenal incidentaloma. Eur J Endocrinol. 2011;164:851–870.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Alì A, Pia A, et al. Cyclic Cushing’s syndrome due to ectopic ACTH secretion by an adrenal pheochromocytoma. J Endocrinol Invest. 1994;17(11):869–874.
   PubMed Web of Science ®Google Scholar
• Beuschlein F, Weigel J, Saeger W, et al. Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab. 2015;100(3):841–849.
   PubMed Web of Science ®Google Scholar
• Miller BS, Gauger PG, Hammer GD, et al. Proposal for modification of the ENSAT staging system for adrenocortical carcinoma using tumor grade. Langenbecks Arch of Surg. 2010;395:955–961.
   PubMed Web of Science ®Google Scholar
• Berruti A, Terzolo M, Sperone P, et al. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Endocr Relat Cancer. 2005;12:657–666.
   PubMed Web of Science ®Google Scholar
• Abiven G, Coste J, Groussin L, et al. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J Clin Endocrinol Metab. 2006;91(7):2650–2655.
   PubMed Web of Science ®Google Scholar
• Berruti A, Fassnacht M, Haak H, et al. Prognostic role of overt hypercortisolism in completely operated patients with adrenocortical cancer. Eur Urol. 2014;65(4):832–838.
   PubMed Web of Science ®Google Scholar
• Schulick RD, Brennan MF. Long-term survival after complete resection and repeat resection in patients with adrenocortical carcinoma. Ann Surg Oncol. 1999;6:719–726.
   PubMed Web of Science ®Google Scholar
• Huynh KT, Lee DY, Lau BJ, et al. Impact of laparoscopic adrenalectomy on overall survival in patients with nonmetastatic adrenocortical carcinoma. J Am Coll Surg. 2016;223:485–492.
   PubMed Web of Science ®Google Scholar
• Brix D, Allolio B, Fenske W, et al. Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients. Eur Urol. 2010;58:609–615.
   PubMed Web of Science ®Google Scholar
• Porpiglia F, Fiori C, Daffara F, et al. Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer. Eur Urol. 2010;57:873–878.
   PubMed Web of Science ®Google Scholar
• Amini N, Margonis GA, KIm Y, et al. Curative resection of adrenocortical carcinoma: rates and patterns of postoperative recurrence. Ann Surg Oncol. 2016;23:126–133.
   PubMed Web of Science ®Google Scholar
• Lee C, Salem AI, Schneider GF, et al. Minimally invasive resection of adrenocortical carcinoma: a multi-institutional study of 201 patients. J Gastrointest Surg. 2017;21(2):352–362.
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Deandreis D, Al Ghuzlan A, et al. Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol. 2010;162(6):1147–1153.
   PubMed Web of Science ®Google Scholar
• Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J Endocrinol. 2013;169:891–899.
   PubMed Web of Science ®Google Scholar
• Erdogan I, Deutschbein T, Jurowich C, et al. The role of surgery in the management of recurrent adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:181–191.
   PubMed Web of Science ®Google Scholar
• Young RB, Bryson MJ, Sweat ML, et al. Complexing of DDT and o,p’DDD with adrenal cytochrome P-450 hydroxylating systems. J Steroid Biochem. 1973;4:585–591.
   PubMedGoogle Scholar
• Schteingart DE, Motazedi A, Noonan RA, et al. Treatment of adrenal carcinomas. Arch Surg. 1982;117:1142–1146.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Angeli A, Fassnacht M, et al. Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med. 2007;356:2372–2380.
   PubMed Web of Science ®Google Scholar
• Berruti A, Grisanti S, Pulzer A, et al. Long-term outcomes of adjuvant mitotane therapy in patients with radically resected adrenocortical carcinoma. J Clin Endocrinol Metab. 2017;102:1358–1365.
   PubMed Web of Science ®Google Scholar
• Postlewait LM, Ethun CG, Tran TB, et al. Outcomes of adjuvant mitotane after resection of adrenocortical carcinoma: a 13-institution study by the US adrenocortical carcinoma group. J Am Coll Surg. 2016;222:480–490.
   PubMed Web of Science ®Google Scholar
• Else T, Williams AR, Sabolch A, et al. Adjuvant therapies and patient and tumor characteristics associated with survival of adult patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014;99:455–461.
   PubMed Web of Science ®Google Scholar
• Berruti A, Baudin E, Gelderblom H, et al. Adrenal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(suppl. 7):vii131–8.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Daffara F, Ardito A, et al. Management of adrenal cancer: a 2013 update. J Endocrinol Invest. 2014;37:207–217.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Baudin AE, Ardito A, et al. Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection. Eur J Endocrinol. 2013;169:263–270.
   PubMed Web of Science ®Google Scholar
• Faggiano A, Leboulleux S, Young J, et al. Rapidly progressing high o,p’DDD doses shorten the time required to reach the therapeutic threshold with an acceptable tolerance: preliminary results. Clin Endocrinol (Oxf). 2006;64:110–113.
   PubMed Web of Science ®Google Scholar
• Terzolo M, Berruti A. Adjunctive treatment of adrenocortical carcinoma. Curr Opin Endocrinol Diabetes Obes. 2008;15:221–226.
   PubMed Web of Science ®Google Scholar
• Reimondo G, Puglisi S, Zaggia B, et al. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma. Eur J Endocrinol. 2017;177(4):361–367.
   PubMed Web of Science ®Google Scholar
• Daffara F, de Francia S, Reimondo G, et al. Prospective evaluation of mitotane toxicity in adrenocortical cancer patients treated adjuvantly. Endocr Relat Cancer. 2008;15:1043–1053.
   PubMed Web of Science ®Google Scholar
• Nader N, Raverot G, Emptoz-Bonneton A, et al. Mitotane has an estrogenic effect on sex hormone-binding globulin and corticosteroid-binding globulin in humans. J Clin Endocrinol Metab. 2006;91:2165–2170.
   PubMed Web of Science ®Google Scholar
• Allolio B, Fassnacht M. Adrenocortical carcinoma: clinical update. J Clin Endocrinol Metab. 2006;91:2027–2037.
   PubMed Web of Science ®Google Scholar
• Sabolch A, Feng M, Griffith K, et al. Adjuvant and definitive radiotherapy for adrenocortical carcinoma. Int J Radiat Oncol Biol Phys. 2011;80:1477–1484.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Hahner S, Polat B, et al. Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab. 2006;91:4501–4504.
   PubMed Web of Science ®Google Scholar
• Habra MA, Ejaz S, Feng L, et al. A retrospective cohort analysis of the efficacy of adjuvant radiotherapy after primary surgical resection in patients with adrenocortical carcinoma. J Clin Endocrinol Metab. 2013;98:192–197.
   PubMed Web of Science ®Google Scholar
• Polat B, Fassnacht M, Pfreundner L, et al. Radiotherapy in adrenocortical carcinoma. Cancer. 2009;115:2816–2823.
   PubMed Web of Science ®Google Scholar
• Bilimoria KY, Shen WT, Elaraj D, et al. Adrenocortical carcinoma in the United States: treatment utilization and prognostic factors. Cancer. 2008;113:3130–3136.
   PubMed Web of Science ®Google Scholar
• Keskin S, Taş F, Vatansever S. Adrenocortical carcinoma: clinicopathological features, prognostic factors and outcome. Urol Int. 2013;90:435–438.
   PubMed Web of Science ®Google Scholar
• Khan TS, Imam H, Juhlin C, et al. Streptozocin and o,p’DDD in the treatment of adrenocortical cancer patients: long-term survival in its adjuvant use. Ann Oncol. 2000;11:1281–1287.
   PubMed Web of Science ®Google Scholar
• Libé R, Borget I, Ronchi CL, et al. Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study. Ann Oncol. 2015;26:2119–2125.
   PubMed Web of Science ®Google Scholar
• Berruti A, Terzolo M, Pia A, et al. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Cancer. 1998;83:2194–2200.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Terzolo M, Allolio B, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366:2189–2197.
   PubMed Web of Science ®Google Scholar
• Bellantone R, Ferrante A, Boscherini M, et al. Role of reoperation in recurrence of adrenal cortical carcinoma: results from 188 cases collected in the Italian national registry for adrenal cortical carcinoma. Surgery. 1997;122:1212–1218.
   PubMed Web of Science ®Google Scholar
• Deschamps F, Farouil G, Ternes N, et al. Thermal ablation techniques: a curative treatment of bone metastases in selected patients? Eur Radiol. 2014;24:1971–1980.
   PubMed Web of Science ®Google Scholar
• Wood BJ, Abraham J, Hvizda JL, et al. Radiofrequency ablation of adrenal tumors and adrenocortical carcinoma metastases. Cancer. 2003;97:554–560.
   PubMed Web of Science ®Google Scholar
• Wong E, Jacques S, Bennett M, et al. Complete response in a patient with stage IV adrenocortical carcinoma treated with adjuvant trans-catheter arterial chemo-embolization (TACE). Asia Pac J Clin Oncol. 2018;14:279–281.
   PubMed Web of Science ®Google Scholar
• Roca E, Berruti A, Sbiera S, et al. Topoisomerase α 2 and thymidylate synthase expression in adrenocortical cancer. Endocr Relat Cancer. 2017;24:299–307.
   PubMed Web of Science ®Google Scholar
• D’avolio A, de Francia S, Basile V, et al. Influence of the CYP2B6 polymorphism on the pharmacokinetics of mitotane. Pharmacogenet Genomics. 2013;23:293–300.
   PubMed Web of Science ®Google Scholar
• Ronchi CL, Sbiera S, Volante M, et al. CYP2W1 is highly expressed in adrenal glands and is positively associated with the response to mitotane in adrenocortical carcinoma. PLoS One. 2014;9(8):e105855.
   PubMed Web of Science ®Google Scholar
• Volante M, Terzolo M, Fassnacht M, et al. Ribonucleotide reductase large subunit (RRM1) gene expression may predict efficacy of adjuvant mitotane in adrenocortical cancer. Clin Cancer Res. 2012;18:3452–3461.
   PubMed Web of Science ®Google Scholar
• Sperone P, Ferrero A, Daffara F, et al. Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer. 2010;17:445–453.
   PubMed Web of Science ®Google Scholar
• Henning JEK, Deutschbein T, Altieri B, et al. Gemcitabine-based chemotherapy in adrenocortical carcinoma: a multicenter study of efficacy and predictive factors. J Clin Endocrinol Metab. 2017;102:4323–4332.
   PubMed Web of Science ®Google Scholar
• Naing A, Kurzrock R, Burger A, et al. Phase I trial of cixutumumab combined with temsirolimus in patients with advanced cancer. Clin Cancer Res. 2011;17:6052–6060.
   PubMed Web of Science ®Google Scholar
• Berruti A, Sperone P, Ferrero A, et al. Phase II study of weekly paclitaxel and sorafenib as second/third-line therapy in patients with adrenocortical carcinoma. Eur J Endocrinol. 2012;166:451–458.
   PubMed Web of Science ®Google Scholar
• Kroiss M, Quinkler M, Johanssen S, et al. Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial. J Clin Endocrinol Metab. 2012;97:3495–3503.
   PubMed Web of Science ®Google Scholar
• Fassnacht M, Berruti A, Baudin E, et al. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015;16:426–435.
   PubMed Web of Science ®Google Scholar
• Le Tourneau C, Zarwan C, Hoimes C, et al. Avelumab in patients with metastatic adrenocortical carcinoma (mACC): results from the JAVELIN solid tumor trial. ESMO Congress; 2017; Madrid, meeting abstract.
   Google Scholar
• Veytsman I, Nieman L, Fojo T. Management of endocrine manifestations and the use of mitotane as a chemotherapeutic agent for adrenocortical carcinoma. J Clin Oncol. 2009;27:4619–4629.
   PubMed Web of Science ®Google Scholar
• Corcuff JB, Young J, Masquefa-Giraud P, et al. Rapid control of severe neoplastic hypercortisolism with metyrapone and ketoconazole. Eur J Endocrinol. 2015;172:473–481.
   PubMed Web of Science ®Google Scholar
• Claps M, Cerri S, Grisanti S, et al. Adding metyrapone to chemotherapy plus mitotane for Cushing’s syndrome due to advanced adrenocortical carcinoma. Endocrine. 2018;61(1):169–172.
   PubMed Web of Science ®Google Scholar
• Abiven-Lepage G, Coste J, Tissier F, et al. Adrenocortical carcinoma and pregnancy: clinical and biological features and prognosis. Eur J Endocrinol. 2010;163(5):793–800.
   PubMed Web of Science ®Google Scholar
• Eschler DC, Kogekar N, Pessah-Pollack R. Management of adrenal tumors in pregnancy. Endocrinol Metab Clin North Am. 2015;44(2):381–397.
   PubMed Web of Science ®Google Scholar
• Assié G, Letouzé E, Fassnacht M, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet. 2014;46:607–612.
   PubMed Web of Science ®Google Scholar
• Zheng S, Cherniack AD, Dewal N, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell. 2016;29:723–736.
   PubMed Web of Science ®Google Scholar